Eurizon Capital SGR S.p.A. Acquires Shares of 1,297,933 Boston Scientific Corporation $BSX

Key Points

• Eurizon Capital SGR disclosed a new fourth-quarter stake in Boston Scientific, buying 1,297,933 shares worth about $123.9 million. The position represents roughly 0.09% of the company.
• Boston Scientific is facing some near-term pressure, with recent headlines citing a slowdown in WATCHMAN demand and softer urology sales, which have weighed on the stock and led to a recent downgrade from Wells Fargo.
• Despite the weakness, the company still reported solid quarterly results, beat EPS and revenue estimates, and authorized a $5 billion share buyback, signaling continued confidence from management.

Eurizon Capital SGR S.p.A. acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,297,933 shares of the medical equipment provider's stock, valued at approximately $123,890,000. Eurizon Capital SGR S.p.A. owned about 0.09% of Boston Scientific as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock worth $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC bought a new position in shares of Boston Scientific during the fourth quarter worth $1,477,000. Kepler Cheuvreux Suisse SA bought a new position in shares of Boston Scientific during the third quarter worth $26,955,000. Finally, Waycross Partners LLC bought a new position in shares of Boston Scientific during the fourth quarter worth $2,384,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Argus raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, February 26th. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. Raymond James Financial reaffirmed an "outperform" rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. BTIG Research reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Boston Scientific in a research report on Monday, May 18th. Finally, Citigroup cut their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $87.46.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific NYSE: BSX

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company's stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company's stock.

Boston Scientific Stock Down 1.6%

Shares of BSX stock opened at $48.32 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1 year low of $48.13 and a 1 year high of $109.50. The firm's fifty day moving average price is $60.23 and its two-hundred day moving average price is $78.62. The firm has a market capitalization of $71.82 billion, a P/E ratio of 20.22, a PEG ratio of 0.90 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business earned $0.75 EPS. The company's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.